ADAMTS13 and sickle cell disease: Sickle cell disease mice models appear to show a benefit of recombinant ADAMTS13; administering recombinant ADAMTS13 to these mice reduced hypoxia-reoxygenation induced haemolysis as well as systemic/local inflammation in lungs and kidneys.